Perimeter Solutions management will hold a conference call at 8:30 a.m. ET on Thursday, December 11, 2025 to discuss the transaction. The conference call can be accessed by dialing (877) 407-9764 ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

An announcement from Perspective Therapeutics ( ($CATX) ) is now available. On December 1, 2025, Perspective Therapeutics updated its corporate ...

MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

The mayor, for example, suggested that Long Beach could step up and make women’s sports part of the broader economic profile for the city. Jax Diener, founder and owner of Watch Me! Sports Bar, shared ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Benjamin Ball Associates, a London-based executive coaching and presentation training firm, has announced the extension of its services to professionals and organisations in several new districts ...

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.